Your browser version may not work well with NCBI's Web applications. More information here...
1: Mult Scler. 2008 Sep;14(8):1137-8. Epub 2008 Aug 13.Click here to read Links
Comment in:
Mult Scler. 2009 Apr;15(4):520.

Early relapses after the first dose of natalizumab in active multiple sclerosis patients.

Centonze D, Furlan R, Gasperini C, Salvetti M, Battistini L.

Department of Neuroscience, Neurologic Clinics, Tor Vergata University, Rome, Italy. centonze@uniroma2.it

BACKGROUND: Natalizumab is prescribed in Italy in patients who experienced at least two clinical relapses during a 12-month therapy with other approved immunomodulatory agents. RESULTS: In 7 of 35 patients selected on the basis of these recommendations, we have observed clinical relapses occurring within 24 h after the first dose of natalizumab. CONCLUSION: The mechanism by which a first injection of natalizumab may precipitate a clinical relapse in patients with MS is unknown. We speculate that natalizumab can promote the release of inflammatory mediators from lymphocytes present in the central nervous system at the time of the first infusion, thus favoring the clinical manifestation of a pre-existing active lesion.

PMID: 18701574 [PubMed - indexed for MEDLINE]

Patient Drug Information

  • Glatiramer Acetate (Copaxone, Avonex, Rebif, ...)

    How effective are disease-modifying drugs in the treatment of multiple sclerosis?

  • Natalizumab Injection (Tysabri® )

    Natalizumab is used to prevent episodes of symptoms and slow the worsening of disability in patients with relapsing forms (course of disease where symptoms flare up from time to time) of multiple sclerosis (MS; a disease...

  • Source: AHFS Consumer Medication Information